NKTRNektar Therapeutics
Is it safe?
Elevated bankruptcy risk: a balance sheet under strain, quality weak, and heavy debt (CCC). Everything else is secondary until this clears.
Elevated financial-distress risk Altman Z-score, a bankruptcy-risk model from five balance-sheet ratios.
Weak, deteriorating fundamentals Piotroski F-score, nine pass/fail tests of year-over-year financial health across profitability, balance sheet and efficiency. 7 to 9 is strong, 0 to 3 weak.
Insiders were net sellers (-$43K, 90 days to Oct 8, 2026), selling is often routine.
Debt against weak or negative operating profit. A rule of thumb on leverage, not a credit rating.
Large price swings, high volatility. Worst drawdown -100% · now 59% below its 52-week high.
Unless marked, from SEC EDGAR, as of Dec 31, 2025.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can NKTR take a bad year?
The deepest fall in NKTR's price history on file is −100%; it is 59% below its high today.
Altman Z-score · distress below 1.8 · safe above 3 · distress zone, the model puts this in the bankruptcy range
- Cash runway
- 2.9 years
Cash runway · burning $59M a quarter at the current rate
- Annualised volatility
- 144%
Annualised volatility · three times the market's own swing
- Worst drawdown on file
- −100%
Worst drawdown on file · −59% today
Details›
- Cash and short-term investments
- $684M
- EBITDA, trailing twelve months
- −$140M
- Operating profit, trailing twelve months
- −$141M
- Annualised volatilitytwo years of daily moves
- 144%
- Worst drawdown on file
- −100%
- Below its 52-week high
- 59%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.